Peer-reviewed veterinary case report
Pentoxifylline versus meloxicam for treating dog osteoarthritis
By Parlak, Kurtuluş et al.·Published in Veterinary medicine and science·2025·Department of Surgery·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Pentoxifylline in Dogs With Osteoarthritis: Comparative Treatment and Efficacy Analysis With Meloxicam.
- Species:
- dog
Plain-English summary
A group of dogs with osteoarthritis, a painful joint condition, was treated with either meloxicam or pentoxifylline to see which worked better. The dogs receiving meloxicam showed greater pain relief at 30 and 60 days, while those on pentoxifylline had lower levels of certain inflammatory markers in their blood. Both treatments had similar effects on overall joint health, but pentoxifylline may help improve blood flow and reduce inflammation. This suggests that while meloxicam is effective for pain, pentoxifylline could be a useful addition in managing osteoarthritis in dogs.
People also search for: dog osteoarthritis treatment · meloxicam for dogs pain relief · pentoxifylline for dog arthritis
Abstract
BACKGROUND: Osteoarthritis is a chronic joint disease that affects dogs and humans alike, with nonsteroidal anti-inflammatory drugs (NSAIDs) being the primary drug treatment for pain relief. This study hypothesised that pentoxifylline could be a potent therapeutic option for canine osteoarthritis, offering superior benefits compared to meloxicam. The study aimed to mitigate inflammation and degeneration, safeguard joint integrity, and assess pentoxifylline's potential as a safer and more effective alternative to NSAIDs in osteoarthritis management. METHODS: 12 dogs with stifle osteoarthritis were divided into two groups: meloxicam (0.1 mg/kg, subcutaneous) and pentoxifylline (10 mg/kg, intramuscular). Clinical, radiological and biochemical examinations were conducted on days 0, 15, 30 and 60. RESULTS: The pain scores were significantly lower in the meloxicam group on days 30 and 60 (p < 0.05). However, both groups had similar scores for other clinical evaluations (p > 0.05). Serum C-reactive protein (CRP) levels were lower in the pentoxifylline group on days 15 and 30, and serum IL-1β levels were lower on days 15, 30 and 60 (p < 0.05). Moreover, cartilage oligomeric matrix protein (COMP) and bone alkaline phosphatase (bALP) levels in the pentoxifylline group showed a significant reduction on day 15 (p < 0.05). Pentoxifylline reduced osteocalcin in serum and hyaluronic acid concentrations in synovial fluid on days 15 and 30 (p < 0.05). However, the level of cross-linked C-telopeptide of type 2 collagen in urine significantly decreased following meloxicam treatment. CONCLUSION: Meloxicam relieves pain by protecting joint cartilage, while even low doses of pentoxifylline enhance joint perfusion and combat inflammation. Future research should explore higher pentoxifylline doses and its potential synergy with NSAIDs for superior osteoarthritis management.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40434930/